ICER will assess the comparative clinical effectiveness and value of therapies for hereditary angioedema, a rare condition characterized by attacks of deep tissue swelling within the skin and/or mucosa. The report is expected to focus on four therapies for the prevention of hereditary angioedema attacks: lanadelumab (Shire), which is currently under review by the FDA with an approval decision expected in August of 2018, and three C1 esterase inhibitors (Haegarda^®, CSL Behring; Cinryze^®, Shire; and Ruconest^®, Pharming*). This list is tentative and subject to change.

*Ruconest (Pharming) was removed from the ICER review in September 2018 because the treatment is no longer under consideration for FDA approval for long-term prophylaxis.